First-in-class EA2-targeted therapeutics
Precision immune modulation for durable remission in autoimmune disease
We develop small-molecule EA2 inhibitors to modulate upstream immune activation—aiming for long-term control without broad immunosuppression.
Preclinical program — no approved products.
Autoimmune diseases are common—affecting over 300 million people worldwide, and up to one in ten in high-income countries. Standard care often relies on broad immunosuppression. These drugs reduce inflammation but suppress healthy immune function, increasing vulnerability to serious infections and some cancers. Toxicity often accumulates, forcing dose changes or drug switching, and many patients still lack durable remission. Most therapies do not address the drivers of disease.
There is an urgent need for targeted, safer therapies that deliver durable disease control without global immune suppression.
The problem
Chronic inflammation, disability, reduced quality of life and cause high healthcare costs.
Why targeted?
Most treatments blunt the entire immune system. EA2 aims to modulate upstream activation selectively.
Our focus
Rare indications and refractory patients with high unmet need and potential orphan pathways.